A Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SHR7390 Combined With SHR-1210 in Patients With Advanced Solid Tumors

Trial Profile

A Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SHR7390 Combined With SHR-1210 in Patients With Advanced Solid Tumors

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs INCSHR 1210 (Primary) ; SHR 7390 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Jiangsu Hengrui Medicine Co.
  • Most Recent Events

    • 17 Jul 2017 Planned initiation date changed from 1 Jun 2017 to 1 Jul 2017.
    • 12 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top